Sex Differences in Growth Hormone Response to GHRH Stimulation Testing

The diagnosis of Growth Hormone Deficiency (GHD) is a complex process, often relying on stimulation tests. Intriguingly, GHD is diagnosed disproportionately more often in males than in females. While some of this disparity may be due to ascertainment bias (how patients are identified), a comprehensive, plausible biological mechanism to fully explain this observed sexual dimorphism in GHD prevalence has remained elusive.

This clinical trial aimed to establish several key findings regarding GHRH testing and its sex-specific implications. The primary objective was to determine if healthy male and female subjects, alongside those with growth hormone (GH) deficiency, exhibit sexually dimorphic (sex-specific) GH responses following GHRH administration. The researchers also sought to uncover if GH responses to GHRH in both control and GH-deficient patients correlate with the expression and activity of specific stimulatory G proteins, namely G alpha q and G alpha S (guanine nucleotide-binding proteins, crucial cellular messengers), further investigating if these G protein levels themselves correlate with gonadal steroid levels. The study's central hypothesis was that sexually dimorphic GH responses to GHRH would be significantly enhanced when comparing individuals in Tanner Stage V (adult sexual maturity) to those in Tanner Stage 1 (prepubertal stage). While the abstract outlines these ambitious aims, it does not provide specific numerical results, percentages, or p-values from the completed study, thus preventing a quantitative comparison of treatment versus control groups or the reporting of specific fold-changes.